ERBB2 and breast cancer: Examples include ado-trastuzumab emtansine (Kadcyla) for HER2-positive breast cancer [24], brentuximab vedotin (Adcetris) for Hodgkin lymphoma and systemic anaplastic large-cell lymphoma [25], and enfortumab vedotin (Padcev) for metastatic urothelial cancer [26].